The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

PLXNA3  -  plexin A3

Homo sapiens

Synonyms: 6.3, HSSEXGENE, PLXN3, PLXN4, Plexin-4, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of PLXNA3

  • The median time was 7.2 months to a first positive chlamydia test result and 6.3 months to a repeat positive test result among those with repeat visits [1].
  • The number of SSCP bands detected in serum samples from patients with chronic hepatitis, either mild (8.1 +/- 3.9), moderate (8.0 +/- 3.3), or severe (9.2 +/- 3.3), and in patients with liver cirrhosis, either compensated (8.0 +/- 2.9), decompensated (6.3 +/- 2.9), or with superimposed hepatocellular carcinoma (9.5 +/- 2.9), was similar [2].
  • One hundred and three children with antibody against hepatitis B e antigen and normal alanine aminotransferase (ALT) levels were followed for 0.6 to 12.5 years (mean, 6.3 years) [3].
  • In the other sample the corresponding figures were 6.3 x 10(4) to 5.5 x 10(5) copies/ml and 5.7 x 10(4) to 7.5 x 10(4) HIV RNA equivalents/ml [4].
  • BNIP3 mRNA levels were 3.0- and 6.3-fold lower in chronic pancreatitis and pancreatic cancer compared to the normal pancreas, respectively [5].

Psychiatry related information on PLXNA3

  • RESULTS: During 21 046 person-years of follow-up (median follow-up, 6.3 years), 199 women developed dementia, including 159 who developed AD [6].
  • Rebleeding occurred in 5 of 61 (8.2%) patients in the endoscopic therapy group, compared with 21 of 85 (24.7%) in the medical therapy group (P = .01), for a pooled relative risk of 0.35 (95% confidence interval, 0.14-0.83; number needed to treat, 6.3) [7].
  • At 12 months (6 months after the intervention ended), social support was higher (4.4 versus 4.1; P = 0.03), self-efficacy was higher (7.2 versus 6.2; P = 0.02), couples communication was higher (3.5 versus 3.1; P = 0.03), and fatigue was lower (5.1 versus 6.3; P = 0.02) in the experimental group compared with the control group [8].
  • In age-adjusted analyses, the Physical Component Summary score was on average 3.4 points lower in women with depression alone and 6.3 points lower in women with PTSD than in women with neither (P<.001) [9].
  • Longitudinally, after adjusting for potentially confounding variables, active asthma predicted subsequent panic disorder (OR = 4.5; 95% CI, 1.1, 20.1), and the presence of panic disorder predicted subsequent asthma activity (OR = 6.3; 95% CI, 2.8, 14.0) [10].

High impact information on PLXNA3


Chemical compound and disease context of PLXNA3

  • Results of a CBC and biochemical profile revealed marked eosinophilia (6.3 X 10(3)/microL; reference interval 0.1-1.2 X 10(3)/microL), moderate thrombocytopenia, and increased activities of alanine aminotransferase, aspartate aminotransferase, and creatine kinase [16].
  • Captopril increased the insulin-mediated disposal of glucose, as compared with placebo, from 5.7 +/- 2.4 to 6.3 +/- 2.5 mg per kilogram of body weight per minute (P less than 0.05), whereas hydrochlorothiazide caused a decrease from 6.4 +/- 2.0 to 5.7 +/- 1.9 (P less than 0.01) [17].
  • As compared with the placebo group, the children who received vitamin A recovered more rapidly from pneumonia (mean, 6.3 vs. 12.4 days, respectively; P less than 0.001) and diarrhea (mean, 5.6 vs. 8.5 days; P less than 0.001), had less croup (13 vs. 27 cases; P = 0.03), and spent fewer days in the hospital (mean, 10.6 vs. 14.8 days; P = 0.01) [18].
  • RESULTS: In intention-to-treat analysis at month 6, participants in the BT and sibutramine group lost a mean (SD) of 7.8 kg (6.3 kg) and had an 8.5% (6.8%) reduction in BMI, which was significantly more than weight loss of 3.2 kg (6.1 kg) and reduction in BMI of 4.0% (5.4%) in the BT and placebo group [19].
  • The average annual hazard rate of endometrial cancer as a first event within the first 5 years of follow-up in the randomized, tamoxifen-treated group was 1.2/1000 patient-years; the cumulative hazard rate was 6.3/1000 [20].

Biological context of PLXNA3

  • The first intron, intron 1, exists in the 5'-noncoding region, 83 base pairs upstream from the ATG start site and is 6.3 kb long [21].
  • Among women with a FM> or =24 kg, carriers of the T allele showed a 6.3 mmHg higher diastolic blood pressure (DBP) than non-carriers whereas no difference was found in women with a FM less than 24 kg [22].
  • When samples of the First European Union Concerted Action HSV Proficiency Panel were tested, 2x10(3) to 5x10(3) HSV type 1 genome equivalents (GE) per ml, i.e., 2.5 to 6.3 GE per run, could consistently be detected [23].
  • Culture results were confirmed by a sensitive duckling infectivity assay that indicated that 6.3 log10 of infectious duck HBV had been inactivated by photochemical decontamination [24].
  • RESULTS: GG, GA and AA genotype frequencies were similar among the patients (53.1%, 41.0, 5.9) and controls (51.6%, 42.1, 6.3; P = 0.92) [25].

Anatomical context of PLXNA3

  • A second vector in which F.IX expression was controlled by the human EF1alpha promoter was constructed and injected into the portal vein of adult C57BL/6 mice at a dose of 6.3 x 10(10) particles [26].
  • Three derived resistant cell lines displayed 2.1-fold (O-129/DDP4, low), 4.1-fold (O-129/DDP8, moderate) and 6.3-fold (O-129/DDP16, high) resistance, respectively, to cisplatin, compared with the sensitive parental line O-129 [27].
  • Northern blot analysis revealed that the highest levels of the 6.3 kilobase (kb) CFTR mRNA were expressed in the colon, with expression also noted in uterus, lung, stomach, and small intestine [28].
  • CYP1A2 mRNA in the primary culture of chimeric mouse hepatocytes in mice No. 1, 2, and 3 was significantly increased 3.8-, 6.3-, and 3.3-fold by 5 microM beta-NF exposure, respectively, compared with the 0.1% DMSO treated control (p<0.01) [29].
  • Mean homologous red blood cell use per patient was 2.9(+/- 0.1) U (institutional range, 0.4 to 6.3 U) [30].

Associations of PLXNA3 with chemical compounds


Other interactions of PLXNA3

  • Rac specifically interacts with the cytosolic domain of plexin-B1, but not with that of plexin-A3 or -C1 [36].
  • Exercise training also reduced local iNOS expression by 52% (from 6.3 +/- 1.2 to 3.0 +/- 1.0 relative U; p = 0.007 vs. control group) [37].
  • The human peptides alphaCGRP, AM, and amylin induced relaxation with mean pEC50 values of 8.6, 6.8, and 6.3 M, respectively [38].
  • Functional studies showed that RNPS1 and ADD1 exerted multiple antitumor actions in OVCA cells, while PLXNA3 only inhibited cell invasiveness [39].
  • A 24-h exposure to 10 nM FdUrd led to inhibition of TS, a 2.5-fold increase in total thymidylate synthase protein content, profound dTTP depletion and a 6.3-fold increase in the ratio of dATP to dTTP, but did not cause single-strand breaks in DNA [40].

Analytical, diagnostic and therapeutic context of PLXNA3

  • The patients were divided into two groups according to pretreatment viral load: the low viral load group (N = 25, <6.3 x 10(5) copies/ml), and the high viral load group (N = 87, > or =6.3 x 10(5) copies/ml) who were additionally administered IFN-beta thrice weekly for subsequent 14 weeks at the patients' request [41].
  • During that period, the mean length of hospitalization decreased (from 21.9 to 12.6 days; P less than 0.0001), inpatient physical therapy decreased (from 7.6 to 6.3 sessions; P less than 0.04), and the maximal distance walked before discharge fell (from 27 to 11 m [93 to 38 ft]; P less than 0.0001) [42].
  • RESULTS: Among the various subgroups, the standardized mortality ratio for the patients on dialysis who were awaiting transplantation (annual death rate, 6.3 per 100 patient-years) was 38 to 58 percent lower than that for all patients on dialysis (annual death rate, 16.1 per 100 patient-years) [43].
  • At the maximal tolerated dose, the peak plasma levels of ddI were 6.3 to 9.6 mumol per liter 0.6 to 1 hour after oral administration; the mean plasma half-life was 1.5 hours [44].
  • Oxygen uptake during shoveling was similar to that for arm ergometry (5.7 vs 6.3 metabolic equivalents), but lower than for treadmill testing (9.3 metabolic equivalents) [45].


  1. Incident Chlamydia trachomatis infections among inner-city adolescent females. Burstein, G.R., Gaydos, C.A., Diener-West, M., Howell, M.R., Zenilman, J.M., Quinn, T.C. JAMA (1998) [Pubmed]
  2. Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b infection [correction of interferon]. López-Labrador, F.X., Ampurdanès, S., Giménez-Barcons, M., Guilera, M., Costa, J., Jiménez de Anta, M.T., Sánchez-Tapias, J.M., Rodés, J., Sáiz, J.C. Hepatology (1999) [Pubmed]
  3. Clinical and histological outcome after hepatitis B e antigen to antibody seroconversion in children with chronic hepatitis B. Ruiz-Moreno, M., Otero, M., Millán, A., Castillo, I., Cabrerizo, M., Jiménez, F.J., Oliva, H., Ramon y Cajal, S., Carreño, V. Hepatology (1999) [Pubmed]
  4. Direct and quantitative detection of HIV-1 RNA in human plasma with a branched DNA signal amplification assay. Urdea, M.S., Wilber, J.C., Yeghiazarian, T., Todd, J.A., Kern, D.G., Fong, S.J., Besemer, D., Hoo, B., Sheridan, P.J., Kokka, R. AIDS (1993) [Pubmed]
  5. Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Erkan, M., Kleeff, J., Esposito, I., Giese, T., Ketterer, K., Büchler, M.W., Giese, N.A., Friess, H. Oncogene (2005) [Pubmed]
  6. Reproductive period and risk of dementia in postmenopausal women. Geerlings, M.I., Ruitenberg, A., Witteman, J.C., van Swieten, J.C., Hofman, A., van Duijn, C.M., Breteler, M.M., Launer, L.J. JAMA (2001) [Pubmed]
  7. Endoscopic therapy versus medical therapy for bleeding peptic ulcer with adherent clot: a meta-analysis. Kahi, C.J., Jensen, D.M., Sung, J.J., Bleau, B.L., Jung, H.K., Eckert, G., Imperiale, T.F. Gastroenterology (2005) [Pubmed]
  8. A randomized clinical trial of a psychoeducational intervention to improve outcomes in systemic lupus erythematosus. Karlson, E.W., Liang, M.H., Eaton, H., Huang, J., Fitzgerald, L., Rogers, M.P., Daltroy, L.H. Arthritis Rheum. (2004) [Pubmed]
  9. Burden of medical illness in women with depression and posttraumatic stress disorder. Frayne, S.M., Seaver, M.R., Loveland, S., Christiansen, C.L., Spiro, A., Parker, V.A., Skinner, K.M. Arch. Intern. Med. (2004) [Pubmed]
  10. Asthma and panic in young adults: a 20-year prospective community study. Hasler, G., Gergen, P.J., Kleinbaum, D.G., Ajdacic, V., Gamma, A., Eich, D., Rössler, W., Angst, J. Am. J. Respir. Crit. Care Med. (2005) [Pubmed]
  11. The association between sleep apnea and the risk of traffic accidents. Cooperative Group Burgos-Santander. Terán-Santos, J., Jiménez-Gómez, A., Cordero-Guevara, J. N. Engl. J. Med. (1999) [Pubmed]
  12. Inadequate management of blood pressure in a hypertensive population. Berlowitz, D.R., Ash, A.S., Hickey, E.C., Friedman, R.H., Glickman, M., Kader, B., Moskowitz, M.A. N. Engl. J. Med. (1998) [Pubmed]
  13. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. Diel, I.J., Solomayer, E.F., Costa, S.D., Gollan, C., Goerner, R., Wallwiener, D., Kaufmann, M., Bastert, G. N. Engl. J. Med. (1998) [Pubmed]
  14. Determinants of preterm birth rates in Canada from 1981 through 1983 and from 1992 through 1994. Joseph, K.S., Kramer, M.S., Marcoux, S., Ohlsson, A., Wen, S.W., Allen, A., Platt, R. N. Engl. J. Med. (1998) [Pubmed]
  15. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., Simonneau, G., Bégaud, B. N. Engl. J. Med. (1996) [Pubmed]
  16. Fatal hepatic sarcocystosis in a puppy with eosinophilia and eosinophilic peritoneal effusion. Allison, R., Williams, P., Lansdowne, J., Lappin, M., Jensen, T., Lindsay, D. Veterinary clinical pathology / American Society for Veterinary Clinical Pathology. (2006) [Pubmed]
  17. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. Pollare, T., Lithell, H., Berne, C. N. Engl. J. Med. (1989) [Pubmed]
  18. A randomized, controlled trial of vitamin A in children with severe measles. Hussey, G.D., Klein, M. N. Engl. J. Med. (1990) [Pubmed]
  19. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. Berkowitz, R.I., Wadden, T.A., Tershakovec, A.M., Cronquist, J.L. JAMA (2003) [Pubmed]
  20. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. Fisher, B., Costantino, J.P., Redmond, C.K., Fisher, E.R., Wickerham, D.L., Cronin, W.M. J. Natl. Cancer Inst. (1994) [Pubmed]
  21. Characterization and chromosomal mapping of the human thromboxane A2 receptor gene. Nüsing, R.M., Hirata, M., Kakizuka, A., Eki, T., Ozawa, K., Narumiya, S. J. Biol. Chem. (1993) [Pubmed]
  22. Body fat, resting and exercise blood pressure and the angiotensinogen M235T polymorphism: the heritage family study. Rankinen, T., Gagnon, J., Pérusse, L., Rice, T., Leon, A.S., Skinner, J.S., Wilmore, J.H., Rao, D.C., Bouchard, C. Obes. Res. (1999) [Pubmed]
  23. Detection of Herpes simplex virus DNA by real-time PCR. Kessler, H.H., Mühlbauer, G., Rinner, B., Stelzl, E., Berger, A., Dörr, H.W., Santner, B., Marth, E., Rabenau, H. J. Clin. Microbiol. (2000) [Pubmed]
  24. Photochemical inactivation of duck hepatitis B virus in human platelet concentrates: a model of surrogate human hepatitis B virus infectivity. Eble, B.E., Corash, L. Transfusion (1996) [Pubmed]
  25. G-455A polymorphism of the fibrinogen beta gene and deep vein thrombosis. Renner, W., Cichocki, L., Forjanics, A., Köppel, H., Gasser, R., Pilger, E. Eur. J. Clin. Invest. (2002) [Pubmed]
  26. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Nakai, H., Herzog, R.W., Hagstrom, J.N., Walter, J., Kung, S.H., Yang, E.Y., Tai, S.J., Iwaki, Y., Kurtzman, G.J., Fisher, K.J., Colosi, P., Couto, L.B., High, K.A. Blood (1998) [Pubmed]
  27. Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells. Chen, G., Hutter, K.J., Zeller, W.J. Cell Biol. Toxicol. (1995) [Pubmed]
  28. Cloning and sequence analysis of rat cystic fibrosis transmembrane conductance regulator. Fiedler, M.A., Nemecz, Z.K., Shull, G.E. Am. J. Physiol. (1992) [Pubmed]
  29. Induction of human CYP1A2 and CYP3A4 in primary culture of hepatocytes from chimeric mice with humanized liver. Nishimura, M., Yokoi, T., Tateno, C., Kataoka, M., Takahashi, E., Horie, T., Yoshizato, K., Naito, S. Drug Metab. Pharmacokinet. (2005) [Pubmed]
  30. The variability of transfusion practice in coronary artery bypass surgery. Transfusion Medicine Academic Award Group. Goodnough, L.T., Johnston, M.F., Toy, P.T. JAMA (1991) [Pubmed]
  31. Expression and physicochemical characterization of human proliferating cell nuclear antigen. Zhang, P., Zhang, S.J., Zhang, Z., Woessner, J.F., Lee, M.Y. Biochemistry (1995) [Pubmed]
  32. Cloning, functional coexpression, and pharmacological characterisation of human cDNAs encoding NMDA receptor NR1 and NR2A subunits. Le Bourdellès, B., Wafford, K.A., Kemp, J.A., Marshall, G., Bain, C., Wilcox, A.S., Sikela, J.M., Whiting, P.J. J. Neurochem. (1994) [Pubmed]
  33. Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. Chou, S., Marousek, G., Parenti, D.M., Gordon, S.M., LaVoy, A.G., Ross, J.G., Miner, R.C., Drew, W.L. J. Infect. Dis. (1998) [Pubmed]
  34. Existence of a beta3-adrenoceptro and its functional role in the human ureter. Park, Y.C., Tomiyama, Y., Hayakawa, K., Akahane, M., Ajisawa, Y., Miyatake, R., Kiwamoto, H., Sugiyama, T., Kurita, T. J. Urol. (2000) [Pubmed]
  35. Interleukin-10 inhibition of gelatinases in fetal membranes: therapeutic implications in preterm premature rupture of membranes. Fortunato, S.J., Menon, R., Lombardi, S.J., LaFleur, B. Obstetrics and gynecology. (2001) [Pubmed]
  36. The semaphorin receptor plexin-B1 specifically interacts with active Rac in a ligand-dependent manner. Vikis, H.G., Li, W., He, Z., Guan, K.L. Proc. Natl. Acad. Sci. U.S.A. (2000) [Pubmed]
  37. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. Gielen, S., Adams, V., Möbius-Winkler, S., Linke, A., Erbs, S., Yu, J., Kempf, W., Schubert, A., Schuler, G., Hambrecht, R. J. Am. Coll. Cardiol. (2003) [Pubmed]
  38. Investigation of CGRP receptors and peptide pharmacology in human coronary arteries. Characterization with a nonpeptide antagonist. Hasbak, P., Saetrum Opgaard, O., Eskesen, K., Schifter, S., Arendrup, H., Longmore, J., Edvinsson, L. J. Pharmacol. Exp. Ther. (2003) [Pubmed]
  39. Profiling estrogen-regulated gene expression changes in normal and malignant human ovarian surface epithelial cells. Syed, V., Zhang, X., Lau, K.M., Cheng, R., Mukherjee, K., Ho, S.M. Oncogene (2005) [Pubmed]
  40. Biochemical and molecular effects of UCN-01 in combination with 5-fluorodeoxyuridine in A431 human epidermoid cancer cells. Grem, J.L., Danenberg, K.D., Kao, V., Danenberg, P.V., Nguyen, D. Anticancer Drugs (2002) [Pubmed]
  41. High viral eradication with a daily 12-week natural interferon-beta treatment regimen in chronic hepatitis C patients with low viral load. IFN-beta Research Group. Shiratori, Y., Nakata, R., Shimizu, N., Katada, H., Hisamitsu, S., Yasuda, E., Matsumura, M., Narita, T., Kawada, K., Omata, M. Dig. Dis. Sci. (2000) [Pubmed]
  42. The care of elderly patients with hip fracture. Changes since implementation of the prospective payment system. Fitzgerald, J.F., Moore, P.S., Dittus, R.S. N. Engl. J. Med. (1988) [Pubmed]
  43. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. Wolfe, R.A., Ashby, V.B., Milford, E.L., Ojo, A.O., Ettenger, R.E., Agodoa, L.Y., Held, P.J., Port, F.K. N. Engl. J. Med. (1999) [Pubmed]
  44. 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. Lambert, J.S., Seidlin, M., Reichman, R.C., Plank, C.S., Laverty, M., Morse, G.D., Knupp, C., McLaren, C., Pettinelli, C., Valentine, F.T. N. Engl. J. Med. (1990) [Pubmed]
  45. Cardiac demands of heavy snow shoveling. Franklin, B.A., Hogan, P., Bonzheim, K., Bakalyar, D., Terrien, E., Gordon, S., Timmis, G.C. JAMA (1995) [Pubmed]
WikiGenes - Universities